Evogene (EVGN) Revenue & Revenue Breakdown
Evogene Revenue Highlights
Latest Revenue (Y)
$5.64M
Latest Revenue (Q)
$4.19M
Evogene Revenue by Period
Evogene Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $5.64M | 236.72% |
| 2022-12-31 | $1.68M | 80.11% |
| 2021-12-31 | $930.00K | -10.58% |
| 2020-12-31 | $1.04M | 38.11% |
| 2019-12-31 | $753.00K | -56.90% |
| 2018-12-31 | $1.75M | -48.33% |
| 2017-12-31 | $3.38M | -48.30% |
| 2016-12-31 | $6.54M | -41.23% |
| 2015-12-31 | $11.13M | -23.31% |
| 2014-12-31 | $14.51M | -17.46% |
| 2013-12-31 | $17.58M | 2.98% |
| 2012-12-31 | $17.07M | 14.57% |
| 2011-12-31 | $14.90M | - |
Evogene generated $5.64M in revenue during NA 2023, up 236.72% compared to the previous quarter, and up 322.84% compared to the same period a year ago.
Evogene Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $4.19M | 624.91% |
| 2023-12-31 | $578.00K | -84.66% |
| 2023-09-30 | $3.77M | 475.99% |
| 2023-06-30 | $654.00K | 2.03% |
| 2023-03-31 | $641.00K | -2.88% |
| 2022-12-31 | $660.00K | 41.63% |
| 2022-09-30 | $466.00K | 49.36% |
| 2022-06-30 | $312.00K | 31.65% |
| 2022-03-31 | $237.00K | -23.79% |
| 2021-12-31 | $311.00K | 105.96% |
| 2021-09-30 | $151.00K | 11.85% |
| 2021-06-30 | $135.00K | -59.46% |
| 2021-03-31 | $333.00K | -5.13% |
| 2020-12-31 | $351.00K | 11.08% |
| 2020-09-30 | $316.00K | 6.04% |
| 2020-06-30 | $298.00K | 297.33% |
| 2020-03-31 | $75.00K | -35.34% |
| 2019-12-31 | $116.00K | 19.59% |
| 2019-09-30 | $97.00K | -49.48% |
| 2019-06-30 | $192.00K | -44.83% |
| 2019-03-31 | $348.00K | -45.20% |
| 2018-12-31 | $635.00K | 73.02% |
| 2018-09-30 | $367.00K | -3.17% |
| 2018-06-30 | $379.00K | 3.55% |
| 2018-03-31 | $366.00K | -50.14% |
| 2017-12-31 | $734.00K | -1.87% |
| 2017-09-30 | $748.00K | -36.50% |
| 2017-06-30 | $1.18M | 63.38% |
| 2017-03-31 | $721.00K | -38.90% |
| 2016-12-31 | $1.18M | -23.18% |
| 2016-09-30 | $1.54M | -15.04% |
| 2016-06-30 | $1.81M | -10.32% |
| 2016-03-31 | $2.02M | -18.15% |
| 2015-12-31 | $2.46M | -25.57% |
| 2015-09-30 | $3.31M | 24.59% |
| 2015-06-30 | $2.66M | -1.67% |
| 2015-03-31 | $2.70M | -25.80% |
| 2014-12-31 | $3.64M | 15.04% |
| 2014-09-30 | $3.16M | -17.82% |
| 2014-06-30 | $3.85M | -0.18% |
| 2014-03-31 | $3.86M | -12.60% |
| 2013-12-31 | $4.41M | 4.23% |
| 2013-09-30 | $4.23M | -1.95% |
| 2013-06-30 | $4.32M | -6.46% |
| 2013-03-31 | $4.62M | -4.19% |
| 2012-12-31 | $4.82M | 21.45% |
| 2012-09-30 | $3.97M | -2.94% |
| 2012-06-30 | $4.09M | - |
Evogene generated $4.19M in revenue during Q1 2024, up 624.91% compared to the previous quarter, and up 634.85% compared to the same period a year ago.
Evogene Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| RCUS | Arcus Biosciences | $117.00M | $48.00M |
| FATE | Fate Therapeutics | $63.53M | $6.77M |
| CGEN | Compugen | $33.46M | $2.56M |
| SURF | Surface Oncology | $30.00M | - |
| ICCC | ImmuCell | $17.47M | $6.01B |
| CLGN | CollPlant Bio | $10.96M | $98.00K |
| EVGN | Evogene | $5.64M | $4.19M |
| GMDA | Gamida Cell | $1.78M | $890.00K |
| BDRX | Biodexa Pharmaceuticals | $381.00K | $41.50K |
| PLUR | Pluri | $326.00K | $96.00K |
| LEXX | Lexaria Bioscience | $226.21K | $84.00K |
| CKPT | Checkpoint Therapeutics | $103.00K | - |
| CRVS | Corvus Pharmaceuticals | - | - |
| ALDX | Aldeyra Therapeutics | - | - |
| ZVSA | ZyVersa Therapeutics | - | - |
| ONCR | Oncorus | - | - |